|SECTION 16 : ADDITIONAL INFORMATION|
|CHROMITOPE Sodium vial is a sterile, pyrogen-free liquid containing radioactive Chromium 51.|
When transporting an employee for medical assistance, after the employee has had direct contact with a radioactive material, care should be taken to avoid contamination of transport vehicle and medical facility. Skin decontamination and monitoring should be conducted as appropriate.
If ingestion of Chromitope Sodium (containing radioactive chromium 51) inadvertently occurs, the individual may be treated by water hydration or diuresis to facilitate elimination of the radioactive material.
Radioactive materials may pose significant health risks if not properly handled. Personnel who handle radioactive materials should be trained in their use and should follow appropriate precautions for work with these materials.
Chromium 51 decays by electron capture and gamma emission with a physical half-life of 27.7 days. The specific gamma ray constant for Chromium 51 is 0.19 R/hour-millicurie at 1 cm. The first half value layer is 0.2 mm of lead (Pb).
Radiopharmaceuticals should be used only by physicians who are qualified by training and experience in the safe use and handling of radionuclides) and whose experience and training have been approved by the appropriate government agency authorized to license the use of radionuclides.
Dispose of radioactive material in accordance with all local, state, federal and NRC regulations or with the regulations of the country in which the material is used.
Diagnostic agents are intended for use under direction of a physician and under the conditions of use described on the label and in the product’s package insert. As a general precaution, personnel who handle these products should avoid contact (ingestion, inhalation, skin and eye contact) with them.
This material safety data sheet is intended for use by personnel who handle this material as part of their job responsibilities and it does not address the diagnostic use of this material. Information concerning the use of this diagnostic agent should be obtained from the product package insert and other appropriate references.
|MSDS Revision Date:|
|May, 18 2001|
Supersedes: March 20, 2001
Supersedes: March 6, 1992
March 20, 2001: New MSDS for CHROMITOPE Sodium was developed by Bracco Diagnostics, Inc.
March 6, 1992: Bristol-Myers Squibb MSDS for CHROMITOPE Sodium.
|The author of this Material Safety Data Sheet (MSDS) is Bracco Diagnostics Inc. |
|The information contained in this MSDS was obtained by Bracco Diagnostics from sources believed to be accurate and reliable and represents information currently on file and known by Bracco. However, Bracco makes no representation, guaranty or warranty, express or implied, with respect to any such information, and specifically disclaims and assumes no liability resulting from the use, misuse or mishandling of either the product or this MSDS. |
|This MSDS is generated and/or distributed by the Bristol-Myers Squibb Company on behalf of Bracco Diagnostics Inc. Please carefully review all of the information disclosed in this MSDS prior to handling or using the product referenced above. |
Copyright© 1996-2005 Actio Software Corporation. All Rights Reserved.